Research programme: adoptive T-cell therapy - Medigene

Drug Profile

Research programme: adoptive T-cell therapy - Medigene

Alternative Names: Immunotherapy-Medigene Immunotherapies; TCR-modified T-cells-Medigene Immunotherapies

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
  • Developer Medigene Immunotherapies
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jan 2018 Helmholtz Zentrum Munchen and Max Delbruck Center for Molecular Medicine have patent protection for tagged TCR technology in USA
  • 28 Aug 2017 Medigene in collaboration with Delbruck Center for Molecular Medicine plans an investigator-initiated trial for Multiple myeloma
  • 18 May 2016 Medigene plans three trials for Cancer in 2016/2017/2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top